Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedMajor change: version bump to v3.2.0 and an important operating-status notice about government funding and NIH Clinical Center, directing users to official sources.SummaryDifference2%
- Check16 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; removed the 'Back to Top' element.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated to include new drug information for various compounds, including Pembrolizumab and Cisplatin, and has added specific facility locations in Japan. Additionally, the revision number has been updated to v3.0.0.SummaryDifference8%
- Check59 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.